ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigational 12-Week Regimen of Daclatasvir and Sofosbuvir | BMS Newsroom

Daclatasvir-sofosbuvir 12-week regimen resulted in:

96% hepatitis C cure rate among patients with HVC genotype 1 disease (n=80/83)

100% hepatitis C cure rate among patients with HCV genotype 2, 3 and 4 disease (n=26/26)

High HCV cure rates seen with no need to alter existing HIV medication regimens

ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigational 12-Week Regimen of Daclatasvir and Sofosbuvir | BMS Newsroom